Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2013 Financial Results on Thursday, February 7th, at 4

Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2013
        Financial Results on Thursday, February 7th, at 4:30 P.M. EST

PR Newswire

TORONTO, Feb. 4, 2013

TORONTO,  Feb.   4,  2013   /PRNewswire/   -  Transition   Therapeutics   Inc. 
("Transition"  or  the  "Company")  (NASDAQ:  TTHI,  TSX:  TTH)  will  hold  a 
conference call on Thursday,  February 7th, 2013 at  4:30 P.M. EST to  discuss 
Second Quarter Fiscal 2013  financial results.  Dr.  Tony Cruz, Chairman  and 
Chief Executive Officer of  the Company, will host  the call. Transition  will 
announce its financial results for this period in a press release to be issued
prior to the  call. In order  to participate in  the conference call,  please 
call 1-800-773-0519 (North America), 1-212-231-2934 (International). A replay
of  the   conference  call   will  be   available  on   Transition's   website for seven days following the call.

About Transition

Transition is a biopharmaceutical  company, developing novel therapeutics  for 
disease indications with large markets.  Transition's lead product is  ELND005 
for the treatment  of Alzheimer's  disease and  bipolar disorder.  Transition 
also has  an emerging  pipeline of  innovative preclinical  and clinical  drug 
candidates. The other drugs in the pipeline that the Company is developing are
for anti-inflammatory  and  metabolic  indications.  Transition's  shares  are 
listed on the NASDAQ  under the symbol "TTHI"  and the Toronto Stock  Exchange 
under the symbol "TTH". For  additional information about the Company,  please 

Notice to  Readers: Information  contained  in our  press releases  should  be 
considered accurate only as of the date  of the release and may be  superseded 
by more recent information we have disclosed in later press releases,  filings 
with the OSC, SEC or otherwise. Except for historical information, this  press 
release may  contain  forward-looking statements,  relating  to  expectations, 
plans or prospects  for Transition, including  conducting clinical trials  and 
potential efficacy  of  its products.  These  statements are  based  upon  the 
current expectations and beliefs of Transition's management and are subject to
certain risks  and uncertainties  that could  cause actual  results to  differ 
materially from those described in the forward-looking statements. These risks
and uncertainties include  factors beyond  Transition's control  and the  risk 
factors and other  cautionary statements discussed  in Transition's  quarterly 
and annual filings with the Canadian commissions.

SOURCE Transition Therapeutics Inc.


For further information on Transition, or
Dr. Tony Cruz
Chief Executive Officer
Transition Therapeutics Inc.
Phone: 416-260-7770, x.223
Press spacebar to pause and continue. Press esc to stop.